FinBoss.io
CSEN
  • Home
  • Crypto prices
  • Bitcoin on-chain
  • US macro
  • US stocks
  • Guides
  • How we make money
FinBoss.io
Home
Crypto prices
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Guides
How we make money
CSEN
Home
Stocks
AbbVie
AbbVie

AbbVie

ABBVHealth care

Stock · Data from SEC EDGAR 13F · Held by 16 of 87 tracked investors

$285.64
▲ 0.16%
Famous investorshold 16buying 1selling 0
Price (USD)
$285.64
Market cap
$505B
P/E ratio
80.7
Tracked investors holding
16 of 87
Next earnings
30 Oct 2026

AbbVie at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
62out of 100
  • Valuation8
  • Growth49
  • Profitability78
  • Quality92
  • Debt63
  • Stability83
In its favour
  • Nothing notable from the statements.

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 202631 Jul 20263.653.64+0.3%
Mar 202629 Apr 20262.652.62+1.2%
Dec 20254 Feb 20262.712.66+1.9%
Sep 202531 Oct 20251.861.77+5.1%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

7D
+0.08%
1M
+7.74%
3M
+10.13%
YTD
+24.56%
1Y
+25.29%
3Y
+105.60%
5Y
+149.10%
Forward P/E
17.6
Dividend yield
2.43%
52-week low
$190.75
52-week high
$291.40

Chart ABBV

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

16
KF
Ken Fisher
Fisher Investments
0.71%$2,390,069,445▲ +4.5%
Čn
Česká národní banka
Česká národní banka
0.7%$132,818,399▲ +1%
LR
Larry Robbins
Glenview Capital
0.68%$37,472,467New position
Šn
Švýcarská národní banka
Swiss National Bank
0.66%$1,255,358,984▼ -3.8%
Ns
Norský státní fond
Norges Bank
0.64%$6,430,543,942New position
GI
Generali Investments CEE
Generali Investments CEE
0.43%$8,971,218unchanged
CA
Cliff Asness
AQR Capital Management
0.18%$507,114,594▲ +126.7%
IE
Israel Englander
Millennium Management
0.14%$381,605,769▲ +124.4%
SC
Steven Cohen
Point72 Asset Management
0.1%$92,310,611New position
KG
Ken Griffin
Citadel Advisors
0.09%$797,644,194▲ +546.5%
JG
Joel Greenblatt
Gotham Asset Management
0.06%$27,395,292▲ +9.9%
MG
Mario Gabelli
GAMCO Investors
0.03%$3,423,059▼ -10.1%
TR
Thomas Russo
Gardner Russo & Quinn
0.03%$3,122,852unchanged
RD
Ray Dalio
Bridgewater Associates
0.01%$2,963,061▼ -61.2%
JY
Jeff Yass
Susquehanna International Group
0.01%$186,357,286▲ +71.8%
BN
Bill Nygren
Oakmark (Harris Associates)
0%$608,969▼ -9.8%

Frequently asked questions

How much is AbbVie (ABBV) stock?

AbbVie shares trade at $285.64, +0.16% over the last trading day. The price is delayed.

What is the market cap of AbbVie?

The market cap of AbbVie is about $505B and its price-to-earnings ratio (P/E) is 80.7.

Does AbbVie pay a dividend?

The dividend yield of AbbVie is 2.43% a year. The yield can change with the company's decisions.

How has AbbVie stock performed over the last year?

The AbbVie share price changed by +25.29% over 12 months and by +149.10% over 5 years.

Which big investors hold AbbVie?

According to the latest 13F filings, 16 of 87 tracked investors hold AbbVie, for example Ken Fisher, Česká národní banka, Larry Robbins.

When will AbbVie report its next results?

The next earnings report of AbbVie is expected on 30 Oct 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms (Czech)Privacy (Czech)Cookies (Czech)

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

What to watch
  • !Revenue grew only 1.8% a year over 3 years.
  • !It pays out more in dividends than it earns.
  • !The stock is expensive: you pay 80.7 USD for 1 USD of annual earnings.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Expensive

For 1 USD of annual earnings you pay 80.7 USD. Based on next year's estimates 17.6 USD.

P/E
80.7×
P/S
7.8×
EV/EBITDA
18.5×

Is the company growing?

Flat
22
23
24
25

Revenue over 3 years grew 1.8% a year. Last year 10.2%.

Does it make money?

Good
  • Cost of sales 30
  • Research 14.9
  • Operations and selling 22.5
  • Taxes and other 25.9
  • Net profit 6.9

Out of 100 USD of revenue, 6.9 USD is left as net profit.

Is it financially healthy?

Mostly
Cash
6.6B USD
Debt
70.9B USD
Free CF
16.9B USD

It could repay its net debt from free cash flow in 3.8 years.

Does it pay a dividend?

Risky
Yield
2.43%
Of earnings
190%

Over a year you receive roughly 2.43% of the price per share. The payout is more demanding for the company. It has raised the dividend for 8 years in a row.

What do analysts expect?

Buy
Average target
284.79 USD
Vs price
−0%

28 analysts. Their opinion is not a recommendation by FinBoss.io.

Which big investors hold it?

16 of 87

Among the tracked investors, Ken Fisher, Česká národní banka, Larry Robbins and others hold the stock according to 13F filings.

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Dividend per share by year (USD)

* the year has not ended yet. Source: Yahoo Finance.

Ratios

P/E
80.7×
Forward P/E
17.6×
P/B
–
P/S
7.8×
PEG
0.58
EV/EBITDA
18.5×
Gross margin
72.8%
Operating margin
40.0%
Net margin
9.8%
ROE
–
ROA
10.5%
Debt / equity
–
Current ratio
0.8×
Revenue growth
10.2%
Earnings growth
290.4%
Beta
0.23
Dividend
2.43%
Payout ratio
190%